Literature DB >> 6966966

Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells.

W Plunkett, S Chubb, L Alexander, J A Montgomery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6966966

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  22 in total

1.  Dynamic metabolic labeling of DNA in vivo with arabinosyl nucleosides.

Authors:  Anne B Neef; Nathan W Luedtke
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Pharmacokinetic study of fludarabine phosphate (NSC 312887).

Authors:  M R Hersh; J G Kuhn; J L Phillips; G Clark; T M Ludden; D D Von Hoff
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.

Authors:  D H Shevrin; T E Lad; L J Kilton; M A Cobleigh; R R Blough; L L Weidner; N J Vogelzang
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

Review 4.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Membrane transport and the antineoplastic action of nucleoside analogues.

Authors:  F M Sirotnak; J R Barrueco
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

6.  Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.

Authors:  E H Chen; E E Johnson; S M Vetter; B S Mitchell
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center study.

Authors:  L J Kilton; A B Benson; A Greenberg; P Johnson; C Shapiro; R Blough; S French; L Weidner
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

8.  6-N-substituted derivatives of adenine arabinoside as selective inhibitors of varicella-zoster virus.

Authors:  G W Koszalka; D R Averett; J A Fyfe; G B Roberts; T Spector; K Biron; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.

Authors:  D A Carson; D B Wasson; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

10.  Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

Authors:  Francesca Ricci; Alessandra Tedeschi; Enrica Morra; Marco Montillo
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.